摘要
目的:观察联合使用热淋清颗粒和阿奇霉素对非淋菌性尿道炎(NUG)的疗效和安全性。方法:从2007年2月至2008年2月,在男科门诊患者中随机选取男性非淋菌性尿道炎患者共40例。年龄18～42岁,平均29岁。将患者随机分为治疗组和对照组各20例。治疗组联合使用阿奇霉素和热淋清颗粒;对照组仅应用阿奇霉素。患者症状评估采用NIH-CPSI评分表量化。结果:两组在治疗前CPSI评分没有显著差异。治疗后,联合治疗组症状评分改善明显优于单药治疗组(5.2±5.1vs9.2±4.3,P<0.05)。联合治疗组治疗有效率85%,对照组65%,P<0.05。两组患者均未出现严重不良反应。结论:联合使用热淋清颗粒与阿奇霉素治疗NGU效果明显优于单独使用阿奇霉素。通过CPSI评分,联合治疗不仅对症状改善,而且对提高患者生活质量优势明显。对确定最佳疗程提高有效率仍需要进一步研究。
Objectives： To determine the safety and effectiveness of combined Relinqing and azithromycin for the treatment of nongonococeal urethritis （NGU）. Methods： Randomized, clinical trial comparing combined Relinqing and azithromycin, with azithromycin for the treatment of NGU. Forty men were evaluated for Chlamydia trachomatis and Ureaplasma urealyticum infection before therapy and 2 weeks posttreatment. We use CPSI to evaluate the symptom of patients. Results ： Overall clinical cure rates at 2 - weeks were 85% and 65% （ P 〈 0. 05 ） in combined therapy group and azithromycin - treated group respectively. CPSI were significant better in combined therapy group than azithromycin - treated group. No severe complication in both group. Conclusions： Combination of Relinqing and azithromycin was well tolerated and satisfactory clinical cure rates in men with NGU. The combined therapy can decrease CPSI scores better than azithromycin group. The optimal therapy period will be observed in future.
出处
《中国性科学》
2009年第1期7-9,17,共4页
Chinese Journal of Human Sexuality
